TACE + SYSTEMIC
THERAPY COMBINATIONS
TACE's primary limitation is inability to prevent new intrahepatic lesion formation and extrahepatic progression. Adding systemic therapy — anti-angiogenic agents, checkpoint inhibitors, or combinations — addresses this limitation and is now supported by Phase III evidence from EMERALD-1.
analyticsAt a Glance
- check_circleEMERALD-1 (2024): DEB-TACE + durvalumab + bevacizumab significantly improved PFS vs TACE alone — first Phase III success for TACE + immunotherapy
- check_circleTACTICS (2020): TACE + sorafenib (sequential) improved PFS by 11.7 months — established sequential (not concurrent) as the optimal approach
- check_circleLAUNCH trial: TACE + lenvatinib vs lenvatinib alone for BCLC B/C — OS benefit in TACE + lenvatinib arm
- check_circleRationale: TACE releases tumour antigens that prime immune responses — a synergistic substrate for checkpoint inhibitor therapy
Why Combine TACE with Systemic Therapy?
TACE achieves excellent local tumour control within treated segments but has no mechanism to prevent new HCC nodule formation elsewhere in the cirrhotic liver, or to address micro-metastatic haematogenous spread. The majority of HCC patients eventually progress after TACE through one of three patterns: local recurrence at the treated site, new intrahepatic lesion emergence, or extrahepatic spread. Systemic therapy addresses exactly these failure patterns — and the TACE procedure itself may create a more favourable immunological environment for systemic agents to work.
“TACE kills the tumour visibly on imaging. Systemic therapy addresses the invisible disease — the new nodules forming in the cirrhotic liver and the micro-metastatic seeds TACE cannot reach. The combination addresses both problems simultaneously.”
The Immunogenic Rationale for TACE + Checkpoint Inhibitors
TACE-induced tumour necrosis releases damage-associated molecular patterns (DAMPs) and tumour antigens into the circulation — an in-situ vaccine effect similar to cryoablation. In the context of an immune checkpoint inhibitor, these released antigens prime tumour-specific T-cells that can then attack not only the treated lesion but distant disease. This biological synergy is the mechanistic basis for TACE + anti-PD-L1 combinations.
Anti-Angiogenic Rationale for TACE + Sorafenib/Lenvatinib
TACE induces a hypoxia response in the surrounding liver — upregulating VEGF and triggering angiogenesis that re-vascularises the treated tumour, enabling recurrence. Anti-angiogenic agents (sorafenib, lenvatinib) block this VEGF-driven re-vascularisation. Sequential TACE → anti-angiogenic (not concurrent) avoids the problem of anti-angiogenic agents suppressing the collateral vessel growth needed for post-TACE liver recovery.
Key Combination Trial Results
The following data represent the most important Phase II and III trials establishing efficacy for TACE + systemic therapy combinations.
EMERALD-1 (2024): DEB-TACE + Durvalumab ± Bevacizumab vs TACE Alone
Source: Lencioni R et al., Lancet 2024. 616 patients. BCLC A/B HCC. Primary endpoint: PFS.
- Median PFS: TACE + durvalumab + bevacizumab15.0 mo
- Median PFS: TACE alone8.2 mo
- Median PFS: TACE + durvalumab (no bev)10.0 mo
LAUNCH Trial: TACE + Lenvatinib vs Lenvatinib Alone (BCLC B/C Unresectable HCC)
Source: Peng Z et al., J Clin Oncol 2023. 338 patients. BCLC B or C unresectable HCC. Primary endpoint: OS.
- Median OS: TACE + Lenvatinib17.8 mo
- Median OS: Lenvatinib alone11.5 mo
- Median PFS: TACE + Lenvatinib10.6 mo
- Median PFS: Lenvatinib alone6.4 mo
TACE Combination Strategies: An Evidence Overview
A structured overview of the key TACE + systemic therapy combinations, their key trials, and their current clinical status.
| Combination | Key Trial | Phase | Primary Endpoint Result | Current Status |
|---|---|---|---|---|
| TACE + Sorafenib (sequential) | TACTICS (Japan 2020) | Phase II | PFS 25.2 vs 13.5 mo (HR 0.59) — significant PFS benefit | Widely adopted in Japan; used at specialist centres globally — sequential protocol essential |
| DEB-TACE + Durvalumab + Bevacizumab | EMERALD-1 (2024) | Phase III | PFS 15.0 vs 8.2 mo (HR 0.77) — statistically significant | First Phase III positive TACE + ICI combination — expected to change guidelines in 2024–2025 |
| TACE + Lenvatinib | LAUNCH (China 2023) | Phase III | OS 17.8 vs 11.5 mo (HR 0.45) — significant OS benefit | Clinically significant OS benefit — most compelling combination data for BCLC B/C; approved in China |
| TACE + Atezolizumab + Bevacizumab | HEPATIC (ongoing) and TALENTACE (Phase III) | Phase III | Pending — trials ongoing | Investigational — most compelling triplet given established atezolizumab + bevacizumab activity in HCC |
| TACE + Sorafenib (concurrent) | SPACE (2012), TACE-2 (2017) | Phase II/III | PFS: No significant improvement — both trials negative | Concurrent combination failed — established that sequential approach (TACTICS) is necessary |
| TACE + Nivolumab | CheckMate 040 cohort | Phase I/II | ORR 32% — encouraging single-arm activity | Phase III trials pending results — TACE + nivolumab combination under broader investigation |
| TACE + Sintilimab + Bevacizumab (China) | CISL 22-01 (China) | Phase II/III | Preliminary results show significant ORR improvement | Chinese-developed combination — PD-1 inhibitor sintilimab + bevacizumab + TACE; being evaluated in broader populations |
How to Decide if TACE + Systemic Therapy Is Right for You
Not every TACE-eligible patient should receive systemic therapy alongside TACE — the decision is individualised based on disease characteristics, liver function, and systemic therapy eligibility.
- 1
Confirm BCLC Stage and Liver Function
TACE + systemic therapy combinations are validated primarily in BCLC B (intermediate) patients with Child-Pugh A liver function. Child-Pugh B patients are typically not candidates for systemic therapy addition — the hepatotoxicity burden of systemic agents in decompensated cirrhosis is prohibitive.
- 2
Assess Systemic Therapy Eligibility
Anti-angiogenic agents (sorafenib, lenvatinib, bevacizumab) are contraindicated in patients with: active varices at high bleeding risk, recent variceal haemorrhage, uncontrolled hypertension, severe proteinuria, recent thromboembolic events. Immunotherapy (durvalumab) is contraindicated in active autoimmune disease and prior solid organ transplant.
- 3
Choose Sequential vs Concurrent
For anti-angiogenic combinations: sequential protocol only — systemic therapy starts 2–3 weeks after TACE, not concurrently. Concurrent anti-angiogenics suppress post-TACE liver regeneration and worsen outcomes (SPACE, TACE-2 data). For checkpoint inhibitors (EMERALD-1 protocol): durvalumab + bevacizumab started with first TACE cycle.
- 4
Discuss at Hepatobiliary MDT
TACE + systemic therapy combinations have significant toxicity — and the management of anti-angiogenic side effects (hypertension, bleeding risk, hepatotoxicity) alongside TACE-related post-embolisation syndrome requires coordinated multidisciplinary care. These combinations should be managed at a hepatobiliary MDT, not by a single clinician.
- 5
Monitor Response Jointly
Response assessment after TACE + systemic therapy requires evaluation of both local (TACE site) and systemic (new lesions, AFP trajectory) response. Modified RECIST for the TACE-treated lesions and RECIST 1.1 for overall response should both be assessed at 4–8 weekly intervals.
More from the TACE Resource Library
Continue exploring TACE — from combination ablation strategies to post-procedure care and access guides.
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE + RFA and TACE + MWA for HCC 3–7 cm
- HAIC (Hepatic Arterial Infusion Chemotherapy) for Advanced HCC
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- TACE Therapy — Complete Treatment Guide
- Sorafenib for Liver Cancer: Advanced HCC Treatment
Frequently Asked Questions
Common questions about TACE + systemic therapy combinations.
About TACE Combination Therapy
My oncologist is planning TACE and sorafenib together — should these be given at the same time?
Not concurrently — this is one of the most important practical points about TACE + sorafenib. Three randomised trials (SPACE, TACE-2, and others) showed no benefit or even harm from concurrent TACE + sorafenib. The TACTICS trial showed benefit specifically with a sequential protocol: TACE first, then sorafenib started 2–3 weeks after TACE and continued until TACE unresponsiveness or unacceptable toxicity. If your oncologist is planning concurrent administration (sorafenib during the TACE procedure or immediately the day after), this is not the evidence-based approach. Clarify the planned timing with your treating team and refer to the TACTICS protocol if needed.
Can I receive atezolizumab + bevacizumab (Tecentriq + Avastin) alongside TACE?
The combination of atezolizumab + bevacizumab (approved as first-line systemic therapy for advanced HCC based on IMbrave150) is being evaluated alongside TACE in ongoing Phase III trials (TALENTACE, HEPATIC). As of 2024, this combination is investigational — the EMERALD-1 trial used durvalumab + bevacizumab (a different anti-PD-L1 agent with bevacizumab), and this is the most mature Phase III dataset for TACE + ICI. If you are seeking to access TACE + atezolizumab + bevacizumab, clinical trial enrolment is the optimal pathway — and CancerFax can advise on which trials are open at Chinese and Indian centres for your specific disease stage and prior treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Combination TACE + Systemic Therapy?
CancerFax connects patients with specialist hepatobiliary oncologists in China and India who implement TACE combination protocols — reviewing your BCLC stage, liver function, and systemic therapy eligibility to identify the most appropriate combination approach for your HCC.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.